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ABSTRACT 
Leishmania mexicana is one of the causative agents of cutaneous leishmaniasis in humans. There is an 
urgent need to identify new drug targets to combat the disease. Cysteine peptidases play crucial role in 
pathogenicity and virulence in Leishmania spp. and are promising targets for developing new anti-
leishmanial drugs. Genetic drug target validation has been performed on a number of cysteine 
peptidases, but others have yet to be characterized. We targeted 16 L. mexicana cysteine peptidases 
for gene deletion and tagging using CRISPR-Cas9 in order to identify essential genes and ascertain 
their cellular localization. Our analysis indicates that two clan CA, family C2 calpains (LmCAL27.1, 
LmCAL31.6) and clan CD, family C11 PNT1 are essential for survival in the promastigote stage. The 
other peptidases analysed, namely calpains LmCAL4.1, LmCAL25.1, and members of clan CA C51, 
C78, C85 and clan CP C97 were found to be non-essential. We generated a gene deletion mutant 
(ǻpnt1) which was severely compromised in its cell growth and a conditional gene deletion mutant of 
PNT1 (ǻpnt1:: PNT1flox/ǻ pnt1::HYG [SSU DiCRE]). PNT1 localizes to distinct foci on the flagellum 
and on the surface of the parasite. The conditional gene deletion of PNT1 induced blebs and pits on 
the cell surface and eventual cell death. Over-expression of PNT1, but not an active site mutant 
PNT1C134A, was lethal, suggesting that active PNT1 peptidase is required for parasite survival. 
Overall, our data suggests that PNT1 is an essential gene and one of a number of cysteine peptidases 
that are potential drug targets in Leishmania. 
Highlights 
Localization and essentiality study of 16 uncharacterized peptidases in L. mexicana. 
Clan CD family C11 PNT1 is essential for survival of Leishmania mexicana parasites. 
1. Introduction 
Human infective Leishmania parasites are the causative agents of one of the major tropical diseases, 
leishmaniasis. Infections may be life changing (cutaneous form) or even fatal (Visceral form of the 
disease) [1]. Millions of people are at risk of contracting the disease with an estimated 20,000 to 
40,000 deaths occurring each year [2]. L. mexicana, one of the causative agents of the cutaneous form 
of the disease, has several life cycle stages that include amastigotes that live in mammalian 
macrophages and flagellated promastigotes in the sandfly midgut [3]. Leishmania parasites have 
mechanisms by which they evade the host immune system and can survive as well as replicate in the 
harsh environment of phagolysosomes within host phagocytes [4]. Deciphering the molecular 
mechanisms that underlie the pathogenicity, virulence and survival mechanisms of these parasites is 
vital for the design of innovative control measures. 
Leishmania peptidases are among the widely studied virulence factors. These enzymes have been 
implicated in pathogenesis, virulence and cellular remodelling of life cycle stages during 
differentiation of the Leishmania parasite [5, 6]. They are also potential drug targets [7, 8]. Peptidases 
can be divided into different sub groups, Clans and Families, based on their catalytic mechanism and 
primary amino acid sequence in the catalytic domain [9]. There are several families of  peptidases 
identified to date [9], among these L. mexicana encodes members of Aspartic (A), Cysteine (C), 
Metallo- (M), Mixed (P), Serine (S) and Threonine (T) [9]. 
There have been a number of studies investigating the importance of Leishmania cysteine peptidases 
in the life cycle of the parasite. In the cysteine peptidase family, Clan CA family C1 members 
cathepsin L-related peptidases; CPA and CPB play an important role in differentiation and survival of 
Leishmania parasite [10].  Clan CA, family C54 member ATG4 was also found to be important for 
virulence in L. major [11]. Whilst Clan CD C14 member metacaspase, was originally thought to have 
an essential cell cycle role in L. major [12], gene deletion mutants [13] indicate a potential role in cell 
death and in autophagy.  In contrast the phenotype of an L. mexicana metacaspase null mutant 
indicates the enzyme has a role as a negative regulator of amastigote proliferation [14]. No detectable 
phenotype could be observed for L. major Clan CF, Family C15 proglutamyl protease I (PPI)-
deficient mutants, which retained infectivity to macrophages in vitro and mice. However, over-
expression of the active PPI, in L. major impaired differentiation [15]. The aforesaid studies clearly 
highlight the role of cysteine peptidases in the virulence of Leishmania, however, a more 
comprehensive study of the proteolytic capacity of the parasite is required in order to identify and 
validate more potential drug targets. 
In this study, we concentrated our efforts to address the gap in knowledge for 16 Leishmania cysteine 
peptidases in Clan CA, families C2, C51, C78, C85, Clan CD families C11 and C50 and Clan CP, 
family C97.  We used L. mexicana as the species of choice for genetic manipulation due to the well-
established methods for CRISPR-Cas9 genome engineering [16, 17]. 
2. Materials and Methods 
2.1 Plasmid Vector generation and CRISPR-Cas9 strategies  
For U6snRNA strategy the SpCas9 gene was amplified from the plasmid p5RT70DDmyc-FlagCas9 (a 
kind gift from Professor Markus Meissner, University of Glasgow) using primers containing 
5overlap to pNUS-GFPcN NdeI linearized vector, which allows for episomal c-terminal expression 
of GFP fused proteins in Leishmania sp [18]. The plasmid was linearized using NdeI and the 4.2 kb 
SpCas9 fragment purified and cloned using Gibson assembly (NEB) to generate pNUS-Cas9. In order 
to express guide RNAs (sgRNA) using a U6snRNA promoter and terminator as described before for 
Leishmania species [17]. The gRNA cassette was synthesized containing PNT1 specific gRNA 
obtained from EuPaGDT [19], (GCCTTGGCATAGTTCTTGAGC). In order to express both SpCas9 
and gRNA from the same plasmid the synthetic expression cassette was cloned in pNUS-Cas9 
linearized with HindIII using Gibson assembly. The final plasmid (pNUS-Cas9_PNT1.1sgRNA) was 
used for transient expression. Double strand break (DSB) repair was facilitated by providing cells 
with a donor DNA, allowing for homologous recombination, replacement of PNT1 alleles and 
selection of mutants. The donor DNA consists of 1000 bp PNT1 UTR specific regions, amplified 
from Leishmania genomic DNA with primers containing adaptors for cloning using Gateway 
(Thermo Fisher Scientific) into a hygromycin (HYG) resistance gene flanked by 5and 3 untranslated 
regions (UTR) of Leishmania dihydrofolate reductase (DHFR). The donor DNA vector was linearized 
using PacI/PmeI and gel purified prior to transfection.  
A T7RNAPol strategy was used to generate both endogenously tagged genes and null mutants. 
Primers to generate donor DNA and sgRNA were designed using LeishGEdit website and protocol 
therein [16] was followed. Briefly, plasmids containing resistance markers for blasticidin (BSD), 
puromycin (PUR) or neomycin (NEO), flanked by Leishmania specific UTR regions to control 
expression, were used as PCR-templates. For in-fusion endogenous tagging a version of the plasmid 
also containing mNeonGreen fluorescent protein open reading frame (ORF) allowed for N- or C-
terminus modification. Donor DNAs contain suitable region of the plasmid for either deletion or 
tagging of the gene flanked by 30 nt sequence for homologous recombination at the appropriate locus. 
Expression of sgRNA in vivo is driven by a T7 RNA Polymerase (T7RNAPol) promoter added to 
primers containing the sgRNA and a portion of SpCas9 scaffold for annealing to a universal reverse 
primer containing the remaining scaffold for ribonucleoprotein complex assembly. For deletion 
mutants double stranded breaks were introduced at the 5´ and 3´ UTRs of the gene, and recombination 
of both alleles facilitated by transfecting with donor DNAs containing 2 distinct selection markers. 
PCR-synthesized DNAs (1 sgRNA + 1 donor for fluorescent mutants; 2 sgRNA + 2 donors for 
deletion mutants) were pooled prior to transfection into a transgenic L. mexicana cell line expressing 
T7RNAPol and SpCas9 [16]. All relevant primers are listed in Table S1. 
The floxed PNT1 construct was generated as described earlier [20]. Briefly, a DiCre expressing cell 
line was generated in L. mexicana. The first allele of PNT1 was replaced by a LoxP flanked version of 
the gene with a C-terminal GFP tag and confirmed by PCR and flow cytometry after propidium iodide 
staining. The second copy of PNT1 was then deleted by homologous recombination and was replaced 
with a HYG resistance cassette (donor DNA vector described above). It is important to note that 
replacing the first allele with the antibiotic cassette followed by floxing the second allele was 
problematic and led to cell cycle defects. The complementation plasmids were generated by cloning 
PNT1, PNT1C134A in pGL631 (pNUS vector) for episomal expression under the selection of G418 
resistance. PNT1C134A was generated by site directed mutagenesis on the PNT1 pNUS plasmid.  
2.2 Leishmania cell culture and transfection 
The promastigote form of Leishmania mexicana mexicana (MNYC/BZ/62/M379) was cultured at 
25°C in HOMEM which was supplemented with 1% penicillin/streptomycin and 10% heat inactivated 
foetal calf serum. Plasmids and homologous recombination DNA fragments were transfected using 
Human T-Cell kit (Lonza) as described elsewhere [14]. CRISPR-Cas9 guides and donors (Table S1) 
were transfected after mixing with Cytomix buffer (66.67 mM Na2HPO4, 23.33 mM NaH2PO4, 5 mM 
KCl, 50 mM HEPES pH 7.3) combined to 150µM CaCl2, and the electroporation process performed 
using Lonza Nucleofector system, program X-001. The cells were incubated at 25ºC overnight and 
were plated onto 96 well plates after dilution and in presence of antibiotics. Transgenic lines were 
maintained in the following antibiotics and respective concentrations: blasticidin (10 ȝg mL-1), G418 
(50 ȝg mL-1), puromycin (50 ȝg mL-1), hygromycin (50 ȝg mL-1), and nourseothricin (75 ȝg mL-1). 
2.3 Rapamycin induced conditional gene deletion  
The DiCre mediated gene deletion was performed using 200nM rapamycin. Cells were grown at a 
starting cell density of 1 x 105 cells mL-1. Cells were grown for 72 h in the presence of selection 
antibiotics. Thereafter, the cells were split to an initial concentration 1 x 105 cells mL-1 with another 
addition of 200nM rapamycin. The growth curves presented represent cells after the second round of 
rapamycin treatment.  
2.4 Western blot analysis 
1 x 107 cells lysed in NuPAGE sample buffer (supplemented with ȕ-mercaptoethanol) were loaded on 
to a 4-12% NuPAGE Bis Tris Gel and run at 150V in MOPS buffer. The gels were transferred onto a 
PVDF membrane using the wet transfer system XCell II Blot Module of Invitrogen at a constant 
voltage of 30V for 90 min. The blot was blocked with 5% Skimmed Milk (Sigma) for 1 h. Primary 
antibodies were added at the following concentrations: rabbit polyclonal PNT1 antibody- 1:500 
overnight at 4°C, sheep polyclonal OPB antibody-1:20,000 1 h at room temperature. After 3 washes 
in 1X TBST, goat anti rabbit HRP (Promega) and donkey anti-sheep HRP (Santa Cruz) were added at 
1;5000 dilution for 1 h. The blots were washed with 1X TBST and overlayed with Clarity Max 
substrate (BioRad). The blots were developed in a myECL Imager (Thermo Fisher Scientific). 
2.5 Confocal microscopy 
Staining was carried out with 1 x 106 cells from log phase cultures. The cells were washed with 1X 
PBS and fixed with of 4% paraformaldehyde (PFA) for 10 min. The wells were washed twice with 1X 
PBS and excess PFA was quenched with 100 mM glycine for 10 min. The cells were then 
permeabilized using 0.1% Triton X-100 for 10 min. Cells were blocked in 1% BSA for 1 h. The PNT1 
antibody (1:200) diluted in 1% BSA was added to the cells and incubated for 1 h at room temperature. 
The cells were washed thrice with PBS. Anti-rabbit secondary antibody Alexa Fluor 594 (Molecular 
probes) was used at 1:500 dilution for 1 h. Cells were washed thrice in PBS, overlaid with a drop of 
SlowFade Gold Antifade Reagent with 4ƍ,6-diamidino-2-phenylindole - DAPI (Invitrogen). The final 
cell pellet was resuspended in 50 µL PBS and stored at 4°C until ready to image. Stained cells were 
spread on a slide and overlaid with coverslip. For DAPI staining of rapamycin induced cells the 
antibody incubation step was omitted and cells mounted with anti fading mounting medium with DAPI 
(Invitrogen) on slides coated with Poly-L-lysine. For live cell imaging cells were stained with Hoescht 
33342 and immobilized in CyGel as previously described [21]. All images were obtained on a Zeiss 
LSM 880 and processed using Zeiss Zen.  
 
2.6 SEM and TEM 
 
For TEM Leishmania parasites were fixed in 8% formaldehyde, 5% glutaraldehyde in 100mM Sodium 
phosphate buffer pH 7.3 mixed 50:50 with culture medium and incubated for 10 min at room 
temperature. The cells were centrifuged at 1000g for 10 min and resuspended in 4% formaldehyde 
2.5% glutaraldehyde in 100mM phosphate for 30 min. After fixation, the cells were washed with 
100mM phosphate 2 x 10 min and then treated with 1% OsO4 on ice 45 min followed by 100mM 
phosphate 2 x 10 min and the following series of treatments as follows: 1% tannic acid in 100mM 
phosphate 10 min, 100mM phosphate 2 x 10 min, 25% ethanol 15 min, 30% ethanol + 2%UA in dark 
1hr, 50% ethanol 15 min, 50% acetone 15 min, 70% acetone 15 min, 90% acetone 15 min, 100% 
acetone 2 x 15 min, 25% Spurr (R) : 75% acetone 20 min, 50% Spurr (R) : 50% acetone 20 min, 75% 
Spurr (R) : 25% acetone 30 min, 100% Spurr (R) 3 changes 30 min each, and polymerised at 70°C 
overnight. The samples were spun on micro centrifuge as required.  
For SEM, the Leishmania parasites Primary fixation of double strength fixative (8% formaldehyde and 
5% glutaraldehyde) in 0.1M phosphate buffer pH 7.3 mixed 50:50 with culture medium for 10 min 
followed by fixation in 4% formaldehyde and 2.5% glutaraldehyde in 0.1M phosphate buffer for 30 
min. The cells were washed twice in 0.1M phosphate buffer for 10 min each. Post-fixation of 1% 
osmium tetroxide for 45 min on ice. Washed twice in 0.1M phosphate buffer for 10 min each. The 
samples were fixed in 1% tannic acid in 0.1M phosphate buffer for 20 min. Washed twice in 0.1M 
phosphate buffer for 10 min each.  The samples were dehydrated in graded series of ethanol (25-
100%), 15 mins each change. 100% ethanol with hexamethyldisilazane (HMDS), 2 changes and left to 
dry in desiccator overnight. Samples were affixed to SEM stubs and sputter coated with 5nm of 
gold/palladium on Polaron SC7640 sputter coater then imaged using Jeol JSM 6490LV scanning 
electron microscope operating at 8kV accelerating voltage. 
 
3. Results 
3.1 CRISPR-Cas9 gene deletion identifies three essential peptidases. 
The automated algorithms of MEROPS database [9] identified 177 peptidases in the L. mexicana 
genome, 61 being annotated as cysteine peptidases or non-peptidase homologues. The gene models 
and annotation for each of the identified proteins was confirmed in TriTrypDB [22]. 17 C2 non-
peptidase homologues were confirmed to lack a predicted functional peptidase domain and were not 
included in the current study. The cysteine peptidases are distributed in clans and families based on 
sequence, structure and active site residues (Fig. 1A). The L. mexicana cysteine peptidase clans 
identified in MEROPS were Clan CA, CD, CF, CP and PC. Several proteins have only recently been 
identified as having cysteine peptidase activity [23], including Clan CA family C78 [24], family C85 
[25], and PPPDE (Permuted Papain fold Peptidases of dsRNA viruses and Eukaryotes) Clan CP 
family C97 [26] (Fig 1A). The details of the proteins of interest are shown in Table 1. A detailed 
domain analysis of those cysteine peptidases was also performed, which gives more insight into the 
roles of these peptidases (Fig. 1B). The domain information was obtained from the SMART domain 
analysis server [27, 28]. In addition to the peptidase domains that were specific to each family, the 
other identifiable domains were transmembrane, coiled coil domain, WD40 domain, zinc finger 
domain and Pfam DUF domains.  Among all the peptidases in this study, we conducted a detailed 
analysis of the Clan CD C11 peptidase PNT1 [29], which is present in the L. mexicana genome, but 
not annotated in MEROPS. 
To test whether cysteine peptidases of interest (Fig. 1A, Table 1) are essential for parasite survival we 
used CRISPR-Cas9 to attempt to generate null mutants [16].  We first tested a U6 snRNA promoter- 
based CRISPR-Cas9 system for L. mexicana promastigotes on PNT1 and on the 5 calpains we 
examined in this study (CAL4.1, CAL25.1, CAL27.1, CAL31.6 and CAL33.1).  We were unable to 
isolate transfectants for any of the calpains using this system. Among the 6 gene editing attempts, we 
only managed to generate gene targeted mutants for PNT1. The PCR analysis using primers outwith 
the cassette (schematic shown in Fig.2A) confirmed correct integration of the HYG resistance cassette 
and deletion of PNT1 in two out of six clones (Cl3 and Cl4, Fig. 2B).  The promastigotes of Cl3 and 
Cl4 were severely compromised in their cell growth, unable to maintain a long-term viable culture, 
and died (Fig. 2C).  Mutants that retained at least one copy of PNT1 had the same growth rate as the 
parental CRISPR-Cas9 line (Fig. 2C). This indicates that PNT1 is essential for promastigote viability. 
As the U6SnRNA system was apparently only effective against a limited number of targets and we 
could not predict which ones would work, we used an alternative CRISPR-Cas9 system where single-
guide RNA (sgRNA) delivery uses PCR-generated DNA templates transcribed in vivo by a transgenic 
cell line expressing T7 RNA polymerase and SpCas9 [16].  This approach allows knock-in of 
fluorescent tags and generation of gene deletion mutants.   
Initially, the 16 cysteine peptidases were either N or C-terminally tagged with mNeonGreen (Fig. 3A-
M), with fluorescent signal being detected for 13 of the lines. Localisation was classified to distinct 
cellular structures according to Leishmania cellular landmarks [30], Table 1.  The calpains were 
localised to the flagellum (CAL4.1), the flagellar pocket (CAL27.1), small cytoplasmic organelles 
(CAL33.1) and to a lysosome-like compartment within the endomembrane system (CAL25.1 and 
CAL31.6). The two members of C51 and the OTU-like cysteine peptidase were found in small 
cytoplasmic organelles, whilst PPPDE1 and PPPDE3 Clan CP peptidases had a cytosolic expression 
and very low signal. PPPDE4 and PPPDE5 are localised at the endomembrane system and at a distinct 
punctum at the posterior tip of the cell, respectively. Finally, separase localised to the nucleus, 
sometimes exhibiting localised points in the nucleus in cells containing 1 nucleus and 1 kinetoplast 
(1N1K). In cells where mitosis was complete a low and disperse signal at the nucleus was detected.  
PNT1 was tagged at the C-terminus, however, there was no detectable mNeonGreen signal in the 
cells. The C- or N-terminus tagging were apparently lethal for LmxM.09.1300 as no mutants were 
isolated, whilst no mNeonGreen signal was detected for LmxM.33.4000. 
Gene deletion mutants were successfully generated for 13 of the 16 cysteine peptidases, as validated 
by PCR; correct integration of the antibiotic marker for each gene was confirmed and the endogenous 
target gene was absent (Fig. 4, Table 1).  Null mutants were created for 3 of the calpains (CAL4.1, 
CAL25.1 and CAL33.1), both D-alanyl-glycyl endopeptidase-like proteins (LmxM.32.2830, 
LmxM.32.2850), Clan CA C78 (LmxM.33.4000), OTU-like peptidase (LmxM.36.6020), the 5 
PPPDE family proteins (LmxM.09.1310, LmxM.09.1300, LmxM.24.0650, LmxM.31.1330, 
LmxM.32.2260) and separase (LmxM.20.1680). The CRISPR-Cas9 knockout experiments were 
performed by replacing both alleles of the target genes with antibiotic resistance genes, BSD and 
NEO, or BSD and PUR. The absence of a PCR product for the CDS, cells resistant to both antibiotics 
and correct integration of drug resistance markers is strongly indicative of a knockout. Null mutants 
could not be generated for LmCAL27.1, LmCAL31.6 and PNT1, a weak evidence of essentiality, as 
discussed previously [31] since we cannot completely eliminate the possibility of technical failure 
However, we can confirm that at least one of the sgRNAs used to insert the DSB into 5'- and 3'-UTR 
of the gene of interest is functional, since the same sequence was used to facilitate the endogenous 
labeling of the genes. After failure to recover transfectants or generation of mutants retaining a WT 
copy, transfections of the gene were repeated at least 3 times. 
3.2 PNT1 is essential for the viability of L. mexicana. 
PNT1 is a Clan CD (C11) cysteine peptidase that was recently shown to be essential for replication of 
the kinetoplast in T. brucei [29].  The subcellular localization of PNT1 was ascertained in L. mexicana 
by labelling with an antibody raised against an insoluble recombinant protein containing the C11 
domain. PNT1 localizes to the cell body and in the flagellum in distinct intense foci (Fig. 5A,B). 
PNT1 staining was more intense in cells that were in the process of cell division (Fig 5C,D). Western 
blotting supported this cell cycle-dependent expression, as levels of PNT1 decreased as the cells 
approached stationary growth phase (Fig. 5E) 
To gain further insights into the function of PNT1 in L. mexicana we used the DiCre system to carry 
out an inducible deletion of PNT1 [20]. The Cre monomers were expressed constitutively from the 
ribosomal locus (SSU::DiCre). The first allele of PNT1 was floxed and the second copy replaced 
using HYG selectable marker (ǻpnt1::PNT1flox/ǻ pnt1::HYG [SSU DiCRE]). We found that the order 
in which gene replacements were carried out influenced the system efficiency, with single marker cell 
lines resulting in aneuploidy and therefore were not suitable for further analysis. To avoid this 
problem we first integrated the floxed version of PNT1 and subsequently we deleted the second PNT1 
allele using HYG cassette.  
Two ǻpnt1::PNT1flox/ǻ pnt1::HYG [SSU DiCRE] clones (number 4 and 9) were tested for excision of 
the floxed PNT1 after addition of rapamycin, with an expected 3.6 kb DNA PCR fragment being 
evident prior to treatment and the presence of 0.68 kb DNA fragment showing excision after 
rapamycin addition (Fig. 6A). Reduction in PNT1 levels in the induced cell line was confirmed by 
western blot with polyclonal PNT1 antibody (Fig. 6B). Clone 9 was found to have a greater depletion 
of PNT1 than clone 4, possibly because the genetic manipulation led to clone 4 being slightly 
compromised in its growth in the absence of rapamycin (Fig. 6C). To assess further the proliferation 
competence of these parasites after induction the cells were cultured for a period of 72 h in the 
presence of 200nM rapamycin and then diluted to 1 x 105 cells mL-1 in the presence of the same 
concentration of rapamycin, before counting over a five-day period.  Both clones showed a loss of 
viability in comparison with the DiCre parental line (Fig. 6C). Interestingly, the induced PNT1 floxed 
cell line recovered growth after 72 h, possibly due to the presence in the population of cells that had 
not induced the loss of PNT1.  A clonogenic assay was therefore performed in order to test this. The 
ǻpnt1::PNT1flox/ǻ pnt1::HYG [SSU DiCRE] induced cell line was cloned in 96 well plates 72 h after  
rapamycin addition. The clones growing on the plates were checked for excision of the floxed PNT1 
by PCR. It was observed that all the isolated clones retained the floxed PNT1 allele (Fig. 6D), 
suggesting that parasites non-responsive to DiCre induced PNT1 gene deletion are present in small 
numbers and these eventually grow out 72 h after the second addition of rapamycin.  
The only structure that is available for C11 cysteine peptidases is from the gut bacterium 
Parabacteroides merdae [32].  Efforts to purify soluble PNT1 protein for either T. brucei or L. 
mexicana in E.coli or baculovirus expression system were unsuccessful. We were, therefore, unable to 
validate the cysteine peptidase activity of L. mexicana PNT1 using biochemical approaches, so an 
alternative approach was tried. Transfection of L. mexicana with an episome to constitutively 
overexpress GFP tagged PNT1 appeared to be lethal for the parasites, as no viable clones were 
isolated. In contrast, transfection of a GFP tagged PNT1 cysteine active site mutant (PNT1C134A) was 
successful and viable parasites isolated. Taken together our observations indicate that PNT1 is an 
essential gene, and that active PNT1 is required for cell viability. 
3.3 Depletion of PNT1 retains kinetoplast but leads to formation of blebs and pits on the cell 
surface 
In order to analyse the possible role of PNT1 in kinetoplast segregation, as observed in T. brucei [29], 
ǻpnt1::PNT1flox/ǻ pnt1::HYG [SSU DiCRE] cell line was induced with rapamycin and stained with 
DAPI.  These cells were confirmed to have lost PNT1 after induction with rapamycin (Fig 7A). All 
cells had nuclear and kinetoplast configurations consistent with normal cell cycle progression, with no 
loss of kinetoplast observed (Fig. 7B). Scanning electron microscopy analysis of ǻpnt1::PNT1flox/ǻ 
pnt1::HYG [SSU DiCRE] parasites treated for 48 h (second round of induction) with rapamycin 
revealed mutants had blebs and pits on the cell surface (Fig. 7C). Cells with normal morphology were 
also observed in the ǻpnt1::PNT1flox/ǻ pnt1::HYG [SSU DiCRE  cell line, possibly due to the 
presence of non-induced cells.  Transmission electron microscopy analysis of the induced 
ǻpnt1::PNT1 flox /ǻpnt1::HYG [SSU DiCRE] cell line confirmed the presence of intact kinetoplast 
and bulges in the flagellar pocket area, resembling the protuberances observed in SEM images (Fig. 
7D). Taken together our data suggests that PNT1 is essential in Leishmania and that loss of PNT1 
leads to cell death with concurrent formation of blebs and pits on the surface of the parasite.  
4. Discussion 
In the 30 years since the first successful genetic manipulation of Leishmania was published [33] only 
about 200 genes have been targeted for gene deletion [34]. Peptidases, and cysteine peptidases in 
particular, comprise one of the largest groups of genes that have been investigated in this way and 
studies have shown that they play a very important role in parasite survival and virulence [5, 6, 8]. 
Despite this, many more Leishmania cysteine peptidases remain to be studied as potential drug targets 
[23] so we used a variety of bioinformatics tools to interrogate the L. mexicana genome and provide 
an up to date list of encoded cysteine peptidases. This list (Fig. 1) includes several families of genes 
that have only recently been recognised to be cysteine peptidases in Leishmania spp., including Clan 
CA family C78, family C85 and PPPDE Clan CP family C97. In mouse, two Clan CA C78 peptidases 
UfSP1 and UfSP2 act on a ubiquitin like protein, the ubiquitin fold modifier 1(Ufm1) for targeting 
proteins for degradation and other cellular processes akin to the classical ubiquitin molecule [24]. The 
OTU (Ovarian tumor) family Clan CA C85 DUBs are involved in a range a cellular processes. 
Members of this family have been implicated in modulating inflammatory signalling cascades [35], 
immune regulation [36] and inhibition of DNA damage dependent ubiquitination [37].  PPPDE family 
peptidases have been implicated in important role in deubiqutination of proteins involved in crucial 
processes such as cell cycle regulation [26] It will be very important to understand the processes that 
these peptidases and how these work in coordination with the known DUBs in Leishmania spp.  
Genetic manipulations in Leishmania spp. at scale has been challenging due to the requirement for 
creating repair cassettes with long homology arms, the need for sequential rounds of transfection to 
delete two alleles and the presence of supernumerary chromosomes [38] . The recent development of 
a variety of CRISPR-Cas9 approaches in Leishmania [16, 17] has enabled fast and robust methods for 
investigating the function of these peptidases at scale. We used two different systems, here named 
after the promoter used to express the sgRNA, both using SpCas9 to produce the double stranded 
break and facilitate the generation of null mutants in L. mexicana promastigotes. The U6snRNA 
system was adapted from the original report by Sollelis and colleagues [17], using the minimal 
sequences required to promote U6snRNA transcription, comprising the tRNAGln and BOX A and B 
flanked by 5 UTR of U6snRNA. The terminator comprises a 120 bp 3UTR from the U6snRNA 
locus [39]. For our strategy we decided to express both SpCas9 and the sgRNA ectopically and 
transiently, in order to obtain mutants with fewer genetic modifications and retaining virulence. Both 
the plasmid and the donor DNA containing homology regions for recombination in the UTRs of the 
gene to be deleted was transfected together. Our second strategy was reproduced from Beneke and 
colleagues [16] and depends on a cell line expressing SpCas9 and T7RNAPol to drive expression of 
the sgRNA and transfection of two linear DNA fragments produced using PCR: a 130 bp fragment 
(containing a T7 promoter, the sgRNA and the SpCas9 scaffold) and a 30nt fragment corresponding 
to the 5 upstream and 3 downstream to the corresponding sgRNA. Furthermore, in order to increase 
the chances of deleting both alleles of the gene of interest, we transfected cells with 2 sgRNAs 
(targeting the 5 and the 3 ends of the target genes) and donor DNAs having NEO/BSD or BSD/PUR 
resistance cassettes for selection.  
Our study reveals that in our hands the CRISPR-Cas9 approach using the T7RNAPol system worked 
better than the U6snRNA system in L. mexicana. Initially, the clan CD, family C11 PNT1 and the 5 
calpains (CAL4.1, CAL25.1, CAL27.1, CAL31.6 and CAL33.1) were used to test both systems. 
Although we could generate null mutant clones for PNT1 using the U6snRNA, none of the other 5 
calpain genes tested resulted in transfectants, either heterozygotes or null mutants. On the other hand, 
using the T7RNAPol we were able to generate null mutants for 3 out of the 5 calpains (CAL27.1, 
CAL31.6 and CAL33.1) but not for PNT1. This comparison between systems indicated for us that the 
T7RNAPol appears to be more reliable than the U6snRNA system. On the other hand, the U6snRNA 
system has advantages in that it allows for transient expression of Cas9 and the sgRNA and therefore 
can be used in wild type strains and several species of Leishmania. The expression of the sgRNA 
using the U6snRNA promoter, while transient, still allows for the maintenance of the circular vector 
for an extended period, as well as SpCas9 and sgRNA expression. Therefore, once the first allele is 
replaced the second one can still be targeted by sgRNAs and deleted using the donor DNA already 
integrated as a homology template for recombination.  Whilst we were able to generate PNT1 null 
mutant clones using the U6snRNA system, these mutants were not viable and died after several 
passages in culture. Our inability to generate PNT1 null mutants using the T7RNAPol system might 
be explained by the T7RNAPol cell line having a slight loss of fitness in comparison to wild type 
parasites.  Taken together, we believe both systems have advantages and disadvantages that must be 
taken in consideration when choosing which system to use. 
Promastigote null mutants were generated for 13/16 of the cysteine peptidases that were targeted for 
deletion.  For three of the cysteine peptidases null mutants were not isolated. These were provisionally 
ascribed an essential status based on the inability to generate null mutants, either because no 
transfectants were recovered, as observed for PNT1 and CAL27.1, or because an extra copy of the 
gene was retained after double selection as observed to CAL31.6, a gene found on supernumerary 
chromosome 30.  Some of the non-essential peptidases in this list, from Clan CA C78, C85 and Clan 
CP C97 are predicted to be involved in the ubiquitination pathway. It could be that these peptidases 
are redundant given that there are other deubiquitinases in the Leishmania parasite. The roles of these 
peptidases also remain to be investigated in the amastigote form of the parasite. The calpains 
investigated in this study have the catalytic residues that suggest that these should be active in the 
parasite. Of note, depletion of the T. brucei homolog of lmCAL27.1, which is annotated as ClpGM6 
and localizes to the flagellar pocket, leads to shortening of the flagellar attachment zone (FAZ) and a 
transition from a trypomastigote to epimastigote form [40]. A similar deregulation of differentiation 
could be a reason why null mutants for CAL27.1 could not be isolated in Leishmania. The D-alanyl-
glycyl endopeptidase has important role in bacterial proliferation [41] however, their role in 
Leishmania life cycle is yet to be elucidated. Both the D-alanyl-glycyl endopeptidase were found to 
be non-essential for the survival of the parasite, so these enzymes might have redundant roles. The 
finding that Clan CD C50 member, separase, is non-essential in the promastigote stage of the parasite 
is unusual. Separase undertakes the proteolytic cleavage of cohesin molecules at the end of anaphase 
[42-44] which allows cell cycle to proceed. Chromosome segregation cannot proceed until the 
cohesion links are broken by separase. The absolute requirement for cleavage of the cohesion 
molecules by separase and cell cycle progression suggests that the most likely explanation for the 
survival of Leishmania mexicana parasites after deletion of separase is the presence of another 
peptidase with a compensatory role. It could be hypothesised that the most likely candidate is Clan 
CD (C14) metacaspase, which has been implicated in chromosome segregation in L. major [12]. 
DiCre mediated inducible knockout of the single copy PNT1 showed that PNT1 is essential for the 
viability of L. mexicana. CRISPR-Cas9 mediated knockout of PNT1 was lethal. IFA data also shows 
that PNT1 staining is more intense in cells that are dividing and that levels of PNT1 decreased as the 
cells approached stationary phase, suggesting that PNT1 has a role in the cell division of L. mexicana. 
Interestingly, PNT1 did not localize to the kinetoplast and that kinetoplasts were not lost after 
depletion of PNT1 in the DiCre line. In addition, blebs and pits were also formed on the surface of the 
parasites This phenotype is different from RNAi of PNT1 in bloodstream form T. brucei where PNT1 
is exclusively required for the maintenance of the kinetoplast in the parasite.  Additionally, it can also 
be inferred that an active PNT1 is required for the parasite survival. Altogether, our data suggests that 
PNT1 has a cell cycle related function in L. mexicana, which is distinct from maintenance of the 
kinetoplast found in T. brucei. Elucidating the structure of L. mexicana PNT1 will help in drug 
development efforts. 
 
Figure Legends 
Fig. 1: Domain analysis of L. mexicana cysteine peptidases. (A) Distribution in different clans and 
families using the MEROPS classification system [9]. (B) Domain analysis of the 16 cysteine 
peptidases analysed in this study. Various domains are depicted at the side of the image. Analysis was 
done using the SMART domain server.  
Fig. 2: PNT1 deletion mediated by CRISPR-Cas9 U6snRNA system. (A) Diagram of the pNUS-
CAS9_PNT1.1sgRNA plasmid and donor DNA containing PNT1 specific 5 and 3UTR for 
recombination. Diagnostic PCR primers were designed to amplify the integrated HYG cassette, with 
primers binding upstream of the open reading frame (PCR1), and PNT1 full-length (PCR2). (B) 
Diagnostic PCRs of clones obtained after transfection and selection with HYG confirming integration 
of the resistance cassette and presence or absence of PNT1 (C) Proliferation of PNT1 clones 1-6 
compared to WT parasites, cells counted every 24h until 120h. 
Fig. 3: CRISPR-Cas9 mediated tagging of 16 cysteine peptidases. Intracellular localization of 
mNeonGreen tagged cysteine peptidases using live cell imaging of L. mexicana (A-M). DNA was 
stained with Hoescht 33342. Scale bar: 2 ȝm.  
Fig. 4: Confirmation of T7Cas9 mediated gene knockout using PCR. Primers were designed to 
amplify internal regions of the CDS (approximately 400 bp) and the integrated resistance cassette, 
with forward primer binding upstream the integration region and reverse binding to the 5of resistance 
marker, either BSD (blasticidin), NEO (geneticin) or PUR (puromycin). The genomic DNA from the 
clones was used for the PCR. The lanes on the gels show the presence or absence of the CDS of the 
gene of interest and the integration PCRs showing the integration of BSD/PUR or BSD/G418 
resistance cassettes. The arrow adjacent to LmCALP4.1 shows integration of the G418 resistance 
cassette. 
Fig. 5: Subcellular localization of PNT1. Immunofluorescence staining for PNT1 in interphase (A-B) 
and dividing (C-D) cells. DNA was stained with Hoescht 33342 (shown in blue) and PNT1 was 
stained with PNT1 Ab followed by secondary mouse TRITC antibody (Molecular probes)-. Scale bar: 
2 ȝm (C) L. mexicana cell lysates were analysed by Western blot on different days of growth with a 
PNT1 antibody. OPB was used as a loading control. 2d, 3d, 4d and 5d refers to cell extract after 2, 3, 
4 and 5 days of growth respectively. 
Fig. 6: DiCre mediated inducible knockout of PNT1 (A) Left; Schematic representation of the 
genotype of ǻpnt1::PNT1flox/ǻ pnt1::HYG [SSU DiCRE]  before (upper) and after (lower) excision 
with rapamycin. The position of primers and the expected PCR fragment size used to confirm DiCre 
mediated PNT1 excision are highlighted. Right:  Clone 4 and 9 were used for the analysis. Gel image 
shows PCR fragments before and after rapamycin (Rap) induction. (B) Western blot analysis of 
clones 4 and 9 before and after rapamycin induction. EF1-Į was used as a loading control. (C) Growth 
curves of PNT1 clones 4 and 9 before and after induction with rapamycin. The graph shows the effect 
of the second round of rapamycin induction after an initial 72 hr induction. The graph was generated 
by plotting average values from 2 independent experiments  (D) Clones isolated after rapamycin 
induction in PNT1 floxed clone 9. 
Fig. 7: (A) PCR confirmation of the excision of PNT1 floxed clones 4 and 9 after rapamycin treatment 
(B) DAPI staining of ǻpnt1::PNT1flox/ǻ pnt1::HYG [SSU DiCRE]  clone 9 before and after 
rapamycin treatment. Scale bar: 5 ȝm. (C) and (D) SEM and TEM of ǻpnt1::PNT1flox/ǻ pnt1::HYG 
[SSU DiCRE] clone 9 before and after rapamycin treatment. N and K stand for Nucleus and 
Kinetoplast respectively. 
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Table1Summaryof16cysteinepeptidases,theirlocalisationandessentiality.

GeneID Name Family Localisation Genedeletionstatus

LmxM.04.0450 LmCAL4.1 C2 Flagellum Nullmutant
LmxM.25.1480 LmCAL25.1 C2 Endomembrane ?
lysosome
Nullmutant
LmxM.27.0490 LmCAL27.1 C2 Flagellarpocket Nogrowth*
LmxM.30.0460 LmCAL31.6 Smallcytoplasmic
organelles ?
lysosome
ExtraCDS**
LmxM.32.2010 LmCAL33.1 C2 Endomembrane ?dots Nullmutant
LmxM.32.2830 D ?alanyl ?glycyl
endopeptidase ?like
C51 Smallcytoplasmic
organelles
Nullmutant
LmxM.32.2850 D ?alanyl ?glycyl
endopeptidase ?like
C51 Smallcytoplasmic
organelles
Nullmutant
LmxM.33.4000 ubiquitinmodifier ?
specificpeptidase1
C78 Nodetectablesignal Nullmutant
LmxM.36.6020 OTU ?Likecysteine
peptidase
C85 Smallcytoplasmic
organelles
Nullmutant
LmxM.09.1310 PPPDE1putative
peptidasedomain
containingprotein,
putative
C97 Cytoplasm(low
expression)
Nullmutant
LmxM.09.1300 PPPDE2putative
peptidasedomain
containingprotein,
putative
C97 Failedendogenous
tagging
Nullmutant
LmxM.24.0650 PPPDE3putative
peptidasedomain
containingprotein,
putative
C97 Cytoplasm(low
expression)
Nullmutant
LmxM.31.1330 PPPDE4putative
peptidasedomain
containingprotein,
putative
C97 Endomembrane ?
endocytic
Nullmutant
LmxM.32.2260 PPPDE5putative
peptidasedomain
containingprotein,
putative
C97 Endomembrane
endocytic,lysosome
Nullmutant
LmxM.20.1680 Separase C50 Nucleus Nullmutant
LmxM.11.0720 PUF9Target1(PNT1) C11 Cellbodyandflagellum
(foci),
datafromantibody
staining.

Essential,validated
usingCRISPR ?Cas9and
Di ?Cre.
*Nodoubleresistanttransfectantsrecovered
**
Doubleresistantmutantsretainedatleastonecopyofthegene.
